---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-027721"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T04:14:05.684410+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MannKind reports 2024 revenue of $286M, net income of $28M; debt reduced by $236M

## Summary
- Full year 2024 revenue $286M (+43% YoY); Q4 revenue $77M (+31% YoY).
- GAAP net income $27.6M ($0.10 EPS basic) vs loss of $11.9M in 2023; non-GAAP net income $67.7M ($0.25 EPS).
- Reduced debt principal by $236M, remaining $36M convertible notes; year-end cash $203M.
- Afrezza INHALE-1 pediatric trial met primary endpoint; FDA meeting planned 1H 2025 for potential sNDA.
- MNKD-101 Phase 3 interim enrollment target expected by YE 2025; MNKD-201 Phase 1 completed.

## SEC filing metadata
- accession: 0000950170-25-027721
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000095017025027721/0000950170-25-027721-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000095017025027721/mnkd-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-027721
- JSON: https://secwatch.observer/filing/0000950170-25-027721.json
- Plain text: https://secwatch.observer/filing/0000950170-25-027721.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.